CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer

被引：59

作者：

Bastian, Patrick J. ^{[1
,2
,3
]}

Palapattu, Ganesh S. ^{[2
,3
]}

Yegnasubramanian, Srinivasan ^{[2
,3
,6
]}

Rogers, Craig G. ^{[2
,3
]}

Lin, Xiaohui ^{[4
]}

Mangold, Leslie A. ^{[2
,3
]}

Trock, Bruce ^{[2
,3
]}

Eisenberger, Mario A. ^{[2
,3
,4
,7
]}

Partin, Alan W. ^{[2
,3
]}

Nelson, William G. ^{[2
,3
,4
,5
,6
,7
]}

机构：

[1] Univ Munich, Univ Klinikum Grosshadern, Urol Klin & Poliklin, D-81377 Munich, Germany

[2] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA

[3] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD USA

[4] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD USA

[5] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA

[6] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD USA

[7] Johns Hopkins Univ, Sch Med, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

JOURNAL OF UROLOGY | 2008年 / 179卷 / 02期

关键词：

prostate; prostatic neoplasms; tumor markers; biological; glutathione S-transferase pi; neoplasm recurrence; local;

D O I：

10.1016/j.juro.2007.09.038

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose: We have noted that hypermethylation at GSTP1 in the preoperative serum of men with localized prostate cancer predicts early prostate specific antigen failure following surgical treatment. In this study we investigated the hypermethylation profile of several genes in the serum of men with localized and hormone refractory prostate cancer. Materials and Methods: We assayed the serum of 192 men with clinically localized prostate cancer and 18 with hormone refractory metastatic disease. A total of 35 serum samples from patients with negative prostate biopsy served as a negative control. CpG Island hypermethylation status of certain genes was assessed, including MDR1, EDNRB, CD44, NEP, PTGS2, RASSF1A, RAR-beta and ESR1. The results of hypermethylation at GSTP1 were included from a previous study. Results: CpG island hypermethylation at MDR1 was positive in 38.2% of cases without PSA recurrence and in 16.1% of those with biochemical recurrence after radical prostatectomy. DNA hypermethylation at the remaining 7 gene loci was not detected in the serum of patients with localized prostate cancer. In serum from metastatic prostate cancer cases CpG island hypermethylation was detected at MDR1 in 15 (83.3%), EDNRB in 9 (50%), RAR-beta in 7 (38.9%), GTSP1 in 5 (27.8%) and NEP or RASSF1A in 3 (16.7%). CpG island hypermethylation at CD44, PTGS2 or ESR was not detected in any samples. All histologically normal cases were negative for CpG island hypermethylation. Conclusions: DNA hypermethylation at MDR1 was detected in cases of localized prostate cancer. CpG island hypermethylation at several gene loci was detected in men with advanced disease. No single gene was consistently observed to be hypermethylated in men with hormone refractory disease. These results suggest that the CpG island hypermethylation status of a defined panel of genes may be a useful biomarker in men with hormone refractory prostate cancer.

引用

页码：529 / 534

页数：6

共 50 条

[1] CpG island hypermethylation profile in serum of men with clinically localized and hormone refractory metastatic prostate cancer - Comment
Reibenwein, Jochen
[J]. JOURNAL OF UROLOGY, 2008, 179 (02): : 535 - 535
[2] CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer - Comments
Boorjian, Stephen A.
[J]. JOURNAL OF UROLOGY, 2008, 179 (02): : 534 - 535
[3] CPG island hypermethylation profile in preoperative serum of men with clinically localized and hormone refractory metastatic prostate cancer.
Bastian, Patrick J.
Palapattu, Ganesh S.
Yegnasubramanian, Srinivasan
Lin, Xiaohui
Rogers, Craig G.
Mangold, Leslie A.
Trock, Bruce J.
Eisenberger, Mario A.
Partin, Alan W.
Nelson, William G.
[J]. JOURNAL OF UROLOGY, 2007, 177 (04): : 220 - 220
[4] CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer
Ellinger, Joerg
Haan, Kim
Heukamp, Lukas C.
Kahl, Philip
Buettner, Reinhard
Mueller, Stefan C.
Von Ruecker, Alexander
Bastian, Patrick J.
[J]. PROSTATE, 2008, 68 (01): : 42 - 49
[5] Is there a "Curative" role of radiotherapy for clinically localized hormone refractory prostate cancer?
Sanguineti, G
Marcenaro, M
Franzone, P
Tognoni, P
Barra, S
Vitale, V
[J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (03): : 264 - 268
[6] Molecular biomarker in prostate cancer: The role of CpG island hypermethylation
Bastian, PJ
Yegnasubramanian, S
Palapattu, GS
Rogers, CG
Lin, XH
De Marzo, AM
Nelson, WG
[J]. EUROPEAN UROLOGY, 2004, 46 (06) : 698 - 708
[7] Hypermethylation of CpG islands in primary and metastatic human prostate cancer
Yegnasubramanian, S
Kowalski, J
Gonzalgo, ML
Zahurak, M
Piantadosi, S
Walsh, PC
Bova, GS
De Marzo, AM
Isaacs, WB
Nelson, WG
[J]. CANCER RESEARCH, 2004, 64 (06) : 1975 - 1986
[8] IS PRIMARY HORMONE THERAPY EFFICIENT FOR CLINICALLY LOCALIZED PROSTATE CANCER IN JAPANESE MEN?
Miyaji, Yoshiyuki
Kobuke, Makoto
Kusaka, Nobuyuki
Fujita, Ryuji
Kondo, Norio
Hara, Ryoei
Fujii, Tomohiro
Jo, Yoshimasa
Yokoyama, Teruhiko
Nagai, Atsushi
[J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 612 - 612
[9] Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer
Smith, Matthew R.
Cook, Richard J.
Coleman, Robert
Brown, Janet
Lipton, Allan
Major, Pierre
Hei, Yong Jiang
Saad, Fred
[J]. UROLOGY, 2007, 70 (02) : 315 - 319
[10] Benefit of atrasentan in men with hormone refractory prostate cancer metastatic to bone.
Lipton, A
Sleep, DJ
Hulting, SM
Isaacson, JD
Allen, AR
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 428S - 428S

← 1 2 3 4 5 →